The clinical evidence behind modern obesity treatment has grown enormously since 2021. The STEP program for semaglutide, the SURMOUNT program for tirzepatide, and the SELECT cardiovascular outcomes trial have collectively changed how the medical world thinks about obesity treatment. This article walks through the major trials in detail, covers what the data actually shows (not just the press releases), and looks at what’s coming next in the pipeline.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey, and you can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
The STEP (Semaglutide Treatment Effect in People with obesity) program is a series of phase 3 clinical trials run by Novo Nordisk to test semaglutide 2.4 mg weekly injection for chronic weight management.<\/strong> The program enrolled thousands of participants across multiple populations and produced the data that led to Wegovy\u00ae’s FDA approval in June 2021.<\/p>\n Quick Answer: In STEP 1, one-third of semaglutide patients lost 20%+ of their body weight over 68 weeks.<\/p>\n Citation:<\/strong> Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.<\/p>\n Design:<\/strong> Randomized, double-blind, placebo-controlled. 1,961 adults with BMI 30+ (or BMI 27+ with at least one comorbidity). No diabetes. All received lifestyle counseling. Treatment duration: 68 weeks.<\/p>\n Primary results:<\/strong><\/p>\n Responder analysis:<\/strong><\/p>\n Key details people miss:<\/strong> The placebo group also received lifestyle counseling and still only lost 2.4%. This is consistent with what lifestyle intervention alone typically produces in a trial setting. The 12.4 percentage point difference between semaglutide and placebo represents the medication’s true additive effect on top of lifestyle changes.<\/p>\n The weight loss trajectory wasn’t linear. Most weight loss occurred between weeks 8 and 52. By week 60, the curve was starting to flatten. This suggests that most patients approach their maximum response somewhere around 12-15 months.<\/p>\n Adverse events:<\/strong> GI events were the most common. Nausea occurred in 44.2% (vs. 17.4% placebo), diarrhea in 31.5% (vs. 16.2%), and vomiting in 24.8% (vs. 6.4%). Most were mild to moderate and occurred during dose escalation. Only 7.0% of semaglutide patients discontinued due to adverse events (vs. 3.1% placebo).<\/p>\n Citation:<\/strong> Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984.<\/p>\n Design:<\/strong> 1,210 adults with type 2 diabetes, BMI 27+, HbA1c 7-10%. Three arms: semaglutide 2.4 mg, semaglutide 1.0 mg, placebo. 68 weeks.<\/p>\n Results:<\/strong><\/p>\n The lower weight loss compared to STEP 1 is a consistent finding across all GLP-1 trials. Patients with type 2 diabetes lose less weight. Probable reasons: insulin resistance affects fat storage and mobilization, diabetes medications (especially insulin and sulfonylureas) promote weight gain, and there may be fundamental differences in appetite regulation in the diabetic population.<\/p>\n The HbA1c reduction was substantial: -1.6% with semaglutide 2.4 mg and -1.5% with semaglutide 1.0 mg, versus -0.4% with placebo. This dual benefit (weight loss plus glucose control) is why GLP-1 agonists have become first-line therapy for people who have both obesity and type 2 diabetes.<\/p>\n Citation:<\/strong> Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021;325(14):1403-1413.<\/p>\n Design:<\/strong> 611 adults, no diabetes, BMI 30+ (or 27+ with comorbidity). All received 30 individual counseling sessions over 68 weeks plus an 8-week low-calorie diet (1,000-1,200 cal\/day) at the start. This was the most intensive behavioral support in any STEP trial.<\/p>\n Results:<\/strong><\/p>\n The placebo group lost more than in STEP 1 (5.7% vs. 2.4%), confirming that intensive behavioral therapy does add value. But semaglutide still tripled the effect. The combination of intensive behavioral support plus medication produced the highest weight loss in the STEP program (16.0%), though the difference from STEP 1 (14.9%) was modest, suggesting that the medication is the primary driver and behavioral therapy provides incremental benefit.<\/p>\n Citation:<\/strong> Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA. 2022;327(14):1414-1425.<\/p>\n Design:<\/strong> 902 adults took semaglutide 2.4 mg for 20 weeks (run-in period). Those who tolerated it and lost at least some weight were then randomized: continue semaglutide or switch to placebo. 48-week randomized phase.<\/p>\n Results after the randomized phase:<\/strong><\/p>\n This trial settled a debate. Obesity requires ongoing treatment. The two-thirds regain within a year of stopping mirrors what happens with other chronic disease medications. It also showed that continued treatment produces additional weight loss beyond what’s achieved in the first 20 weeks, meaning the drug keeps working even after initial response.<\/p>\n Citation:<\/strong> Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28:2083-2091.<\/p>\n Design:<\/strong> 304 adults, no diabetes. Semaglutide 2.4 mg vs. placebo for 104 weeks (2 years).<\/p>\n Results at week 104:<\/strong><\/p>\n Weight loss was maintained through the full two years. The trajectory shows most weight loss occurring in the first 60 weeks, followed by a plateau that’s maintained through week 104. This is the longest randomized data we have for semaglutide at the obesity dose, and it’s reassuring. The drug doesn’t lose efficacy over two years.<\/p>\n Citation:<\/strong> Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes (STEP 8). JAMA. 2022;327(2):138-150.<\/p>\n This was the first head-to-head trial between two GLP-1 agonists for obesity. Semaglutide 2.4 mg weekly vs. liraglutide 3.0 mg daily for 68 weeks.<\/p>\n Semaglutide produced more than double the weight loss of liraglutide. The convenience of weekly vs. daily dosing was a bonus. This trial effectively made liraglutide a second-line GLP-1 option for obesity.<\/p>\n The SURMOUNT program tested tirzepatide (Eli Lilly’s dual GIP\/GLP-1 receptor agonist) for obesity.<\/strong> Tirzepatide was already approved for type 2 diabetes as Mounjaro\u00ae. The obesity program led to FDA approval of Zepbound\u00ae in November 2023.<\/p>\n Citation:<\/strong> Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.<\/p>\n Design:<\/strong> 2,539 adults, BMI 30+ (or 27+ with comorbidity), no diabetes. Four arms: tirzepatide 5 mg, 10 mg, 15 mg, and placebo. 72 weeks.<\/p>\n Results:<\/strong><\/p>\n Responder analysis (15 mg dose):<\/strong><\/p>\n These numbers are remarkable. More than one in three patients at the highest dose lost at least 25% of their body weight. Some patients lost over 30%. These results overlap with bariatric surgery outcomes.<\/p>\n The 5 mg dose of tirzepatide was essentially comparable to semaglutide 2.4 mg. The additional benefit of the 10 mg and 15 mg doses represents the GIP receptor agonism kicking in (or simply higher GLP-1 receptor engagement, or both).<\/p>\n Adverse events were similar to semaglutide:<\/strong> nausea 24-33% (dose-dependent), diarrhea 18-21%, vomiting 9-13%. Discontinuation due to adverse events: 4.3-7.1% across doses. Notably, GI side effects were somewhat lower with tirzepatide than semaglutide, despite greater weight loss.<\/p>\n Citation:<\/strong> Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.<\/p>\n Design:<\/strong> 938 adults with type 2 diabetes, BMI 27+. Tirzepatide 10 mg, 15 mg, or placebo for 72 weeks.<\/p>\n Results:<\/strong><\/p>\n Again, lower weight loss in the diabetes population than in SURMOUNT-1, but substantially better than semaglutide in STEP 2 (-9.6%). Tirzepatide’s advantage over semaglutide appears to be even larger in the diabetes population.<\/p>\n HbA1c reductions were impressive: -2.1% at the 15 mg dose, bringing the mean HbA1c from 8.0% to 5.9%. That takes many patients from poorly controlled diabetes to near-normal glucose levels.<\/p>\n SURMOUNT-3 tested tirzepatide after a 12-week intensive lifestyle intervention, showing total weight loss of about 26.6% when the lifestyle phase and drug phase were combined. SURMOUNT-4 was the withdrawal design (parallel to STEP 4) and confirmed that weight regain follows discontinuation. Both studies reinforced findings from the earlier SURMOUNT trials.<\/p>\n Citation:<\/strong> Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024.<\/p>\n This was the first anti-obesity medication trial specifically designed for obstructive sleep apnea. Two sub-studies: one in patients using CPAP and one in patients not using CPAP. Tirzepatide 10-15 mg for 52 weeks.<\/p>\n Results showed approximately 50% reduction in the apnea-hypopnea index (AHI), with many patients dropping below the threshold for moderate sleep apnea. Weight loss was 18-20%. This trial expanded tirzepatide’s clinical relevance beyond weight loss into a specific obesity complication and may eventually support a sleep apnea indication.<\/p>\n Citation:<\/strong> Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232.<\/p>\n SELECT is arguably the most important obesity medication trial ever conducted because it proved that treating obesity with medication prevents cardiovascular events. Previous anti-obesity medications had never demonstrated this.<\/p>\n Design:<\/strong> 17,604 adults with overweight or obesity (BMI 27+), no diabetes, established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease). Semaglutide 2.4 mg weekly vs. placebo. Median follow-up: 39.8 months (about 3.3 years), with some patients followed for over 5 years.<\/p>\n Primary endpoint (MACE: cardiovascular death, non-fatal heart attack, non-fatal stroke):<\/strong><\/p>\n That 20% reduction in major adverse cardiovascular events is in the same ballpark as what statins produce. And it occurred in a population that was already on optimal medical therapy (statins, antihypertensives, antiplatelet agents). Semaglutide added cardiovascular protection on top of existing treatment.<\/p>\n Weight loss in SELECT:<\/strong> -9.4% with semaglutide at 104 weeks vs. -0.9% with placebo. Lower than STEP 1’s -14.9%, partly because SELECT enrolled a sicker, older population (mean age 62 years) and partly because the cardiovascular outcome was the primary endpoint, not weight loss.<\/p>\n Why SELECT matters:<\/strong> It shifts the framing of GLP-1 agonists for obesity from “weight loss drugs” to “cardiometabolic disease treatments.” The 20% MACE reduction gives payers (insurance companies, Medicare) a harder argument for not covering these medications. If a drug prevents heart attacks and strokes, it’s harder to classify as cosmetic or elective.<\/p>\n SELECT also produced meaningful improvements in heart failure outcomes, C-reactive protein (a marker of inflammation), and kidney function, suggesting benefits beyond just weight loss and cardiovascular events.<\/p>\n The trials are impressive, but they have real limitations.<\/strong><\/p>\n Clinical trial participants are screened, motivated, receive regular follow-up, and know they might be on placebo. Real-world outcomes are typically somewhat lower than trial outcomes. A 2024 retrospective study by Wharton et al. in Obesity found that real-world semaglutide users lost about 10-12% body weight at 12 months, compared to the 14.9% in STEP 1. Still substantial, but lower.<\/p>\n The longest randomized data we have is STEP 5 at 2 years. SELECT ran for 3+ years but was a cardiovascular outcomes trial, not a weight loss efficacy study. We don’t have 5-year or 10-year randomized weight loss data for semaglutide or tirzepatide at obesity doses. The Swedish Obese Subjects study provided 20-year surgery data. Medications haven’t been around long enough to match that follow-up.<\/p>\n About 39% of weight lost on semaglutide in STEP 1 was lean mass (measured by DEXA). This is comparable to diet-induced weight loss and less lean mass loss than some surgical approaches, but it’s still a concern, particularly for older adults. No STEP or SURMOUNT trial was specifically designed to measure the impact of exercise on lean mass preservation during GLP-1 therapy.<\/p>\n Most STEP and SURMOUNT participants were white women. Hispanic, Black, and Asian populations were represented but underrepresented relative to the demographics of obesity in the U.S. STEP 2 and SURMOUNT-2 focused on diabetes but didn’t examine whether efficacy differs by race or ethnicity. A 2024 post-hoc analysis of STEP 1 found similar efficacy across racial groups, but the sample sizes for subgroup analyses were small.<\/p>\n Adolescents were studied in the STEP TEENS trial (semaglutide in 12-17-year-olds with obesity), which showed 16.1% weight loss, similar to adults. Elderly patients (75+) were largely excluded from the major trials.<\/p>\n Key Takeaway: The SELECT trial proved semaglutide cuts heart attacks and strokes by 20% in people with obesity.<\/p>\n Several next-generation obesity medications are in late-stage clinical development, and some produce even greater weight loss than current options.<\/strong><\/p>\n A triple agonist: GLP-1, GIP, and glucagon receptors. Phase 2 data published in the NEJM in 2023 (Jastreboff et al.) showed up to 24.2% weight loss at 48 weeks at the highest dose, and the weight loss curve was still descending at the end of the trial, meaning the ultimate effect may be even larger. Phase 3 trials are ongoing.<\/p>\n The glucagon receptor agonism is the novel addition. Glucagon increases energy expenditure and promotes fat breakdown, but it also raises blood sugar. The GLP-1 and GIP components counteract that glucose-raising effect. Whether the triple mechanism produces better long-term outcomes than dual agonism remains to be seen.<\/p>\n A dual GLP-1\/glucagon receptor agonist (no GIP). Phase 2 data showed about 18-19% weight loss at 46 weeks. Phase 3 trials for obesity and MASH (metabolic dysfunction-associated steatohepatitis) are underway.<\/p>\n An oral non-peptide GLP-1 receptor agonist. Unlike oral semaglutide (which is still a peptide that needs to be taken on an empty stomach with limited water), orforglipron is a small molecule with fewer absorption restrictions. Phase 2 data in the NEJM showed about 14.7% weight loss at 36 weeks. If phase 3 confirms these results, it would be the first truly convenient oral GLP-1 for obesity.<\/p>\n A co-agonist that combines GLP-1 and amylin receptor agonism. Phase 1 data presented in 2023 showed approximately 13% weight loss in just 12 weeks, an unusually rapid trajectory. Phase 2 trials are ongoing. Amylin is a hormone co-secreted with insulin that slows gastric emptying and reduces appetite through brainstem mechanisms distinct from GLP-1.<\/p>\n A fixed-dose combination of semaglutide 2.4 mg and cagrilintide (a long-acting amylin analog). The REDEFINE 1 phase 3 trial reported approximately 22.7% weight loss at 68 weeks, somewhat better than semaglutide alone. CagriSema may represent an upgrade path for patients already on semaglutide who want additional weight loss.<\/p>\n There’s a gap between the science and the hype, and it’s worth being direct about where the marketing outpaces the data.<\/strong><\/p>\n Marketing claim: “Up to 20% weight loss.”<\/strong> True for averages in the best trials, but about 10-15% of patients have minimal response. The “up to” framing cherry-picks the best responders. A more honest statement would be: “Average weight loss of 15-21%, with a wide range of individual responses.”<\/p>\n Marketing claim: “Revolutionary.”<\/strong> The science is genuinely impressive. But these medications don’t cure obesity. They require ongoing use, produce partial weight loss (not a return to “ideal” weight for most), and have real side effects. They’re a major advance, not a magic solution.<\/p>\n Marketing claim: “Safe and well-tolerated.”<\/strong> The safety profile is favorable, especially compared to older weight loss drugs (fenfluramine\/phentermine, sibutramine) that were pulled from the market for serious harm. But 44% of patients experiencing nausea and 25% experiencing vomiting in STEP 1 isn’t exactly “well-tolerated” for everyone. The thyroid C-cell tumor signal in rodents, while absent in human data so far, means patients with MEN2 or MTC history cannot use these drugs. Gallbladder events are increased. Pancreatitis, while rare (0.1-0.2%), is a serious risk.<\/p>\n Underreported in marketing: weight regain after discontinuation.<\/strong> The STEP 4 and SURMOUNT-4 data show clear and rapid weight regain when medication is stopped. This isn’t a small caveat. It’s the most important limitation of the entire drug class for long-term obesity management, and it’s rarely emphasized in consumer-facing materials.<\/p>\n Underreported: the lean mass loss problem.<\/strong> Losing 39% of total weight as lean mass means losing substantial muscle. In an older adult, this can accelerate sarcopenia and increase fall risk. Resistance training and protein supplementation mitigate this, but no GLP-1 trial has adequately studied or protocolized these interventions.<\/p>\n Bottom line: Real-world weight loss runs about 3-5 percentage points lower than clinical trial results.<\/p>\n Misconceptions about treatment can delay good decisions. Here are three worth correcting before you make any choices about your care.<\/p>\n Myth:<\/strong> Obesity is mostly about willpower. Fact:<\/strong> Obesity is a chronic disease driven by genetics, hormones, brain signaling, and environment. Twin studies show 40 to 70 percent of body weight variation is heritable. Willpower alone has a poor track record against the biology of weight regulation.<\/p>\n Myth:<\/strong> GLP-1 medications are a quick fix. Fact:<\/strong> These medications work as long as you take them. Stop the medication and weight regain typically follows. They’re chronic-disease tools, similar to blood pressure medications, not short-term diet aids.<\/p>\n Myth:<\/strong> You should reach a ‘normal’ BMI to be healthy. Fact:<\/strong> Most cardiometabolic improvements appear with just 5 to 10 percent weight loss. The Look AHEAD and DPP trials both showed major reductions in diabetes risk and cardiovascular markers at this threshold, well before reaching any ‘goal weight.’<\/p>\n Managing your metabolic health shouldn’t be a journey you take alone. The science behind GLP-1 medications offers a new level of hope for people facing obesity and the related challenges that come with it. By addressing root hormonal and metabolic causes, these treatments provide a path toward more stable energy, better cardiovascular health, and improved quality of life.<\/p>\n At TrimRx, we’re committed to providing an empathetic and transparent experience. We understand the frustrations of traditional healthcare: the long waits, the unclear costs, and the lack of personalized care. Our platform is designed to put you back in control of your health. By combining clinical expertise with modern technology, we help you access the treatments you need while providing the 24\/7 support you deserve.<\/p>\n Our program includes:<\/p>\n Sustainable health is about more than a number on a scale or a single lab result. It’s about feeling empowered in your own body. Whether you’re starting to research your options or ready to take the next step with a free assessment, we’re here to guide you with science-backed, personalized care.<\/p>\n Bottom line:<\/strong> TrimRx provides a streamlined, medically supervised path to access the latest advancements in obesity and weight management, all from the comfort of home.<\/p>\n Tirzepatide produces more weight loss on average. SURMOUNT-1 (tirzepatide 15 mg: -20.9%) beats STEP 1 (semaglutide 2.4 mg: -14.9%) by about 6 percentage points. However, there’s no head-to-head trial directly comparing the two drugs. Cross-trial comparisons are imperfect because study populations differ. A head-to-head trial is needed and would be the definitive answer. For now, tirzepatide appears to have the edge in efficacy, with comparable or slightly better tolerability.<\/p>\n All GLP-1 agonists cause nausea in a significant percentage of patients because slowed gastric emptying is part of the mechanism. Oral orforglipron had lower nausea rates in phase 2 (about 25-30% vs. 44% for injectable semaglutide), which could make it more tolerable. Non-GLP-1 options like naltrexone-bupropion (Contrave) cause less nausea but also produce less weight loss (about 5-6%). Phentermine causes stimulant-type side effects (elevated heart rate, insomnia) rather than GI symptoms.<\/p>\n Real-world outcomes are consistently lower than trial results, typically by 3-5 percentage points. A 2024 study using claims data found real-world semaglutide weight loss of about 10-12% at 12 months vs. the trial’s 14.9%. Reasons include lower adherence, inconsistent supply, dose titration issues, and the absence of trial-level follow-up and support. Real-world data for tirzepatide is still emerging.<\/p>\n The thyroid C-cell tumor signal comes from rodent studies. Rats and mice treated with GLP-1 agonists develop medullary thyroid carcinoma. This hasn’t been observed in humans, and the GLP-1 receptor density in rodent thyroid C-cells is much higher than in humans. Pharmacovigilance databases haven’t shown increased thyroid cancer rates in semaglutide or liraglutide users over nearly a decade of real-world use. The boxed warning remains as a precaution, and the drugs are contraindicated in patients with a personal or family history of MTC or MEN2. Other cancers haven’t shown signals of concern in the trials.<\/p>\n Patent expirations for semaglutide (Novo Nordisk) are expected around 2031-2034, depending on jurisdiction and patent challenges. Generic\/biosimilar versions would follow. In the meantime, competition from tirzepatide, orforglipron, and pipeline drugs may exert some pricing pressure. Legislative efforts to allow Medicare to negotiate drug prices or to cover anti-obesity medications would also affect costs. For now, manufacturer copay cards, insurance coverage expansion, and telehealth competition are the main forces reducing out-of-pocket costs.<\/p>\n Several candidates are in or approaching phase 3 trials. Oral semaglutide 50 mg (OASIS 1) has been submitted for FDA review. Orforglipron’s phase 3 program is underway. Retatrutide phase 3 data is expected in 2025-2026. CagriSema’s REDEFINE program results are rolling in. The pipeline is deep, and competition is intense. It’s reasonable to expect 2-3 new obesity drug approvals within the next 2-3 years.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" The clinical evidence behind modern obesity treatment has grown enormously since 2021.<\/p>\n","protected":false},"author":11,"featured_media":76644,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[12],"tags":[],"class_list":["post-76645","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-weight-loss"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/76645","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=76645"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/76645\/revisions"}],"predecessor-version":[{"id":76833,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/76645\/revisions\/76833"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/76644"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=76645"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=76645"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=76645"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}STEP 1: The Flagship Trial<\/h3>\n
\n
\n
STEP 2: Diabetes Population<\/h3>\n
\n
STEP 3: Intensive Behavioral Therapy Combination<\/h3>\n
\n
STEP 4: The Withdrawal Study<\/h3>\n
\n
STEP 5: Two-year Efficacy Data<\/h3>\n
\n
STEP 8: Head-to-head vs. Liraglutide<\/h3>\n
\n
What Are the SURMOUNT Trials?<\/h2>\n
SURMOUNT-1: The Flagship Trial<\/h3>\n
\n
\n
SURMOUNT-2: Diabetes Population<\/h3>\n
\n
SURMOUNT-3 and SURMOUNT-4<\/h3>\n
SURMOUNT-OSA: Sleep Apnea Trial<\/h3>\n
What Did the SELECT Trial Show?<\/h2>\n
\n
What Are the Limitations of the Current Evidence?<\/h2>\n
Trial Populations Don’t Perfectly Represent Real-world Patients<\/h3>\n
Limited Long-term Data<\/h3>\n
Lean Mass Loss Is a Concern<\/h3>\n
Missing Populations<\/h3>\n
What’s in the Drug Pipeline?<\/h2>\n
Retatrutide (Eli Lilly)<\/h3>\n
Survodutide (Boehringer Ingelheim\/Zealand Pharma)<\/h3>\n
Orforglipron (Eli Lilly)<\/h3>\n
Amycretin (Novo Nordisk)<\/h3>\n
CagriSema (Novo Nordisk)<\/h3>\n
What Does the Research Say vs. What Marketing Claims?<\/h2>\n
Myth vs. Fact: Setting the Record Straight<\/h2>\n
The Path Forward with TrimRx<\/h2>\n
\n
FAQ<\/h2>\n
Which Is Better: Semaglutide or Tirzepatide?<\/h3>\n
Are There Obesity Drugs That Don’t Cause Nausea?<\/h3>\n
How Do Obesity Drug Trials Compare to Real-world Outcomes?<\/h3>\n
What About the Cancer Risk Concerns?<\/h3>\n
When Will These Drugs Become Cheaper?<\/h3>\n
Is the FDA Likely to Approve New Obesity Drugs Soon?<\/h3>\n